News Summary
NegativeMedline delivered strong Q3 2026 revenue growth of 10.4% ($7.9B), but this has been severely overshadowed by an FDA warning letter on manufacturing quality violations, remediation costs that impacted Q2 earnings, and multiple sharp stock declines (down to 52-week low of $31.37). Ongoing securities fraud investigations by multiple law firms and significant analyst downgrades reflect loss of investor confidence despite solid topline performance.
Red flags
- •FDA warning letter (June 2, 2026) detailing significant violations of Current Good Manufacturing Practice regulations
- •Acknowledged remediation efforts resulted in material earnings loss in Q2 2026
- •Stock declined 7% on June 2, 13% on August 5, and 12.8% in early October; now at 52-week low of $31.37
- •Multiple securities fraud investigations by BFA Law, Kirby McInerney, Kaplan Fox, and Pomerantz ongoing as of October 2026
- •Analyst downgrades including Zacks 'strong sell' and price target cuts from Barclays ($45→$43) and BofA ($53→$46)
- •Potential litigation exposure and reputational damage to major healthcare supplier
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 7.0M | +7.0M | $244M | 2.0% | — | NEW |
| Durable Capital Partners | Henry Ellenbogen | 4.7M | +2.1M | $164M | 1.7% | +80% | Existing |
| ValueAct Holdings | Mason Morfit | 4.2M | +4.2M | $144M | 2.3% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where MDLN ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #12 of this fund's book
- 9TOAST INC$237M
- 10LIBERTY LIVE HOLDINGS INC$200M
- 11AGILENT TECHNOLOGIES INC$182M
- 12MEDLINE INC$144M
- 13GALLAGHER ARTHUR J & CO$137M
- 14RYAN SPECIALTY HOLDINGS INC$136M
- 15SIMPSON MFG INC$134M
position #19 of this fund's book
- 16REPLIGEN CORP$272M
- 17MONSTER BEVERAGE CORP NEW$269M
- 18SNOWFLAKE INC$259M
- 19MEDLINE INC$244M
- 20SHERWIN WILLIAMS CO$241M
- 21EQUITY LIFESTYLE PROPERTIES$236M
- 22CAMDEN PPTY TR$230M
position #20 of this fund's book
- 17REVVITY INC$202M
- 18UL SOLUTIONS INC$190M
- 19FLOWSERVE CORP$189M
- 20MEDLINE INC$164M
- 21VSE CORP$142M
- 22WARBY PARKER INC$139M
- 23TTM TECHNOLOGIES INC$133M
Values are quarter-end position sizes. Shown only for funds where MDLN ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Signal History
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| GIC Private Ltd | — | SELL | 7.8M | $35.15 | $274.77M | 2026-10-08 | ↗ |
| GIC Private Ltd | — | SELL | 2.1M | $35.05 | $73.22M | 2026-10-06 | ↗ |
| GIC Private Ltd | — | SELL | 7.2M | $35.05 | $251.76M | 2026-10-06 | ↗ |
| GIC Private Ltd | — | SELL | 1.7M | $35.78 | $60.42M | 2026-10-05 | ↗ |
| GIC Private Ltd | — | SELL | 2.6M | $35.35 | $90.88M | 2026-10-02 | ↗ |
| GIC Private Ltd | — | SELL | 7.1M | $34.33 | $245.35M | 2026-10-02 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Capital Research Global Investors | SC 13G | 47.8M | 5.4% | 2026-11-13 | ↗ |
| GIC Private Limited | SC 13G/A | 74.6M | 8.5% | 2026-11-06 | ↗ |
| GIC Private Limited | SC 13G/A | 114.4M | 13.0% | 2026-10-30 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | SC 13G/A | 61.1M | 6.4% | 2026-08-11 | ↗ |
| BX Mozart ML-2 Holdco L.P. | SC 13G/A | 89.5M | 10.2% | 2026-08-07 | ↗ |
| FMR LLC | SC 13G | 46.9M | 5.5% | 2026-08-06 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.